Tag Archives: GLP-1 receptor agonists

The relationship between GLP-1 therapies and atrial fibrillation is an emerging topic in diabetes care, raising an important question: could medications designed to protect the heart also influence its rhythm? Patients with diabetes already face a higher risk of atrial fibrillation, so understanding how these GLP-1 receptor agonists affect cardiac …

GLP-1 therapies are becoming an important focus in peripheral artery disease, especially as clinicians look beyond glucose control to improve outcomes in high-risk patients. People with diabetes and peripheral artery disease often face a difficult path, marked by poor circulation, delayed wound healing, and a higher risk of amputation. While …

GLP-1 receptor agonists as adjunct therapy in type 1 diabetes are gaining attention as clinicians look for new ways to improve glycemic control. But is this approach a promising tool or a risky shortcut? As emerging evidence builds, providers must balance potential benefits with safety concerns and patient-specific factors. Table …

The risk of side effects with GLP-1 therapies varies widely among patients, yet treatment decisions often overlook this variability. Why do some patients tolerate GLP-1 receptor agonists with ease while others discontinue early? Much like how individuals respond differently to diet or exercise, medication tolerance is influenced by a mix …

The rise of newer incretin-based therapies is changing how clinicians think about diabetes care. But are GLP-1 receptor agonists already being challenged by this next wave of incretin therapy? While these medications have transformed treatment in recent years, newer multi-agonist therapies are gaining attention. As a result, healthcare providers are …

What does success really look like with GLP-1 therapy in 2026? Is it simply lowering A1C, or are clinicians now aiming for something more sustainable like remission or long-term maintenance? As GLP-1 receptor agonists continue to transform diabetes care, the conversation is shifting beyond short-term outcomes. Today, defining clear and …

Managing type 2 diabetes today can feel like navigating a moving target. As new guidelines shift toward personalized, risk-based care, many clinicians ask the same question: how can a diabetes risk stratification approach be applied effectively in daily practice? This evolving approach is not just theoretical. Instead, it offers a …

As the use of GLP-1 receptor agonists expands, clinicians increasingly face a key challenge: how do you manage patients with multimorbidity using GLP-1 therapies? These treatments are no longer limited to glycemic control. Instead, they now play a central role in cardiovascular protection, weight management, and even renal outcomes. However, …

Managing type 2 diabetes today can feel like solving a moving puzzle. With so many therapies available, how do clinicians decide what comes next? GLP-1 therapies have become a key part of today’s diabetes treatment algorithm, helping providers balance glucose control, cardiovascular risk, and patient preferences. As treatment options evolve, …

Type 2 diabetes often feels like a slow-burning fire that gradually damages the body over time. But what if early intervention could help control that fire before it spreads? Research into how GLP-1 therapies support beta-cell function suggests these treatments may do more than lower blood sugar. They may also …